Biosimilar medicines have been the hot subject of debate for a number of years. But as health systems around the world face continued budget squeezes and seek to increase the number of patients treated with biosimilars, the use of these less expensive options becomes ever more pertinent. Today (Tuesday 15th November) patient groups from across […]
EU debate on biosimilar drugs
